$XBI $128 +2%
Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!
ASCO Abstract Release Movers
$SNSE +30% SNS-301 (immunoPhage) - POC - HNSCC 1PR/7SD anti-PD1 fail pts
$PDSB +26% PDS101, M7824 + NHS-IL12 83%ORR HPV+ & 63% HPV- advancd cancer checkpoint fail pts.
$IMMP +16% Efti + pembro 27% ORR in NSCLC and 11% CR and 20%PR in HNSCC
$MRUS -16%
$ALPN -17%
$BDTX -37%
Covid Updates
$SRNE +4% Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Phase 2 Pivotal Clinical Trial of COVI-MSC™ in Hospitalized COVID-19 Patients With Acute Respiratory Distress Syndrome. source
$IMNM -1% Immunome Announces Additional $4.3 Million Award by DOD following Positive Preclinical Testing Results on COVID-19 Variants of Concern. source
$BTNX +2% Pfizer and BioNTech Sign Agreement for Additional Supply to Turkey of 60 Million Doses of their COVID-19 Vaccine. source
$BTNX +2% Pfizer and BioNTech to Supply the European Union with up to 1.8 Billion Additional Doses of COMIRNATY®. source
Pipeline Updates
$AUPH +3% Aurinia To Present Supportive AURORA 2 Continuation Study Interim Analysis Demonstrating Long-Term Safety & Efficacy of LUPKYNIS™ (voclosporin) in Subjects with Lupus Nephritis. source
$OMER -11% OMEROS ANNOUNCES EXTENSION OF FDA REVIEW PERIOD FOR NARSOPLIMAB IN HSCT-TMA. source
$ACRX +6% AcelRx Announces an Investigator-Initiated Study of DSUVIA® in the Emergency Department for Patients with Sickle Cell Disease. source
$ANIX +6% Anixa Biosciences and Moffitt Cancer Center Receive Additional Information Request from US FDA for CAR-T IND Application. source
$XENT +1% Intersect ENT Receives CE Mark Approval for PROPEL® Contour for Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery. source
$OBSV +4% ObsEva Announces Final Results from the Phase 3 PRIMROSE Program of Yselty® (linzagolix) for the Treatment of Uterine Fibroids. source
$SRNE +4% Sorrento Reports Positive Initial Result in Dosing of First Enbrel-Non-Responding Rheumatoid Arthritis Patient With the Sofusa® Lymphatic Drug Delivery Device. source
$BPMC +4% Blueprint Medicines Presents ARROW Trial Data for GAVRETO® (pralsetinib) Highlighting Durable Clinical Activity in Patients with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer and Other Advanced Solid Tumors. source
$IMGN -2% ImmunoGen Announces Mature Data from FORWARD II Study Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Recurrent Ovarian Cancer, Regardless of Platinum Status. source
$ALLO -5% Allogene Therapeutics CD19 Forum Highlights Positive Results from Phase 1 Studies of ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma and Plan to Initiate Pivotal Study in 2021. source
Finance Updates
$YMAB +8% Y-mAbs Enters into Exclusive Distribution Agreement with Adium Pharma S.A. for DANYELZA® (naxitamab-gqgk) and Omburtamab in Latin America. source
Posted by DV